 Home > Active Ingredient News > Antitumor Therapy > NICE recommends Revlimid (lynadamine) for primary treatment of patients with multiple myeloma

NICE recommends Revlimid (lynadamine) for primary treatment of patients with multiple myeloma

 Last Update: 2021-02-03
 Source: Internet
 Author: User

Tags

phase 1 metabolism

1 3 bisphosphoglycerate

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The National Institutes of Health and Care Excellence (NICE) recommends revlimid (lynadamine) from BMS for the initial treatment of patients with multiple myeloma.
INCE recommended Revlimid (Lenadamine) as a maintenance treatment for patients with multiple myeloma who were initially treated after an introphy stem cell transplant (ASCT) in their final evaluation document (FAD).
according to BMS, from today, about 1,150 eligible patients in England will receive Revlimid immediately, with funding from the Cancer Drugs Fund (CDF).
recommendation was supported by two Phase III clinical data, which showed that Revlimid maintenance therapy significantly improved progressive survival (PFS) in patients with primary multiple myeloma compared to placebo.
calGB 100104 study showed that the medium PFS in patients in the Revlimid group was 57.3 months, while the placebo group was 28.9 months.
IFM 2005-02 study showed that the medium PFS in patients in the Revlimid group was 41 months, while the placebo group was 23 months.
, about 1,500 newly diagnosed multiple myeloma patients are treated with ASCT each year, but most eventually relapse.
first remission period is critical for patients with multiple myeloma because it can indicate the overall survival of the disease.
that effective maintenance therapy at this stage of the disease may be "essential" for long-term survival.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.